Coherus Targets $175M Annual LOQTORZI Sales by 2028
ArchivedSingle Source|3 articles|1 sources|1 blocks
Detected: Updated: Analyzed:
Reported Facts
Observable data points shared across all narratives
- •Coherus BioSciences aims for $175 million in annualized LOQTORZI revenue by 2028.
- •The company is accelerating its commercial expansion to meet this sales target.
- •LOQTORZI is a pharmaceutical product marketed by Coherus.
- •The announcement was made on March 10, 2026.
What Could Happen If...
- ▸Coherus successfully expands LOQTORZI sales as planned The company could increase its market share and revenue, benefiting shareholders and potentially improving patient access to the drug.
Market Exposure
StocksCoherus BioSciences Inc. (ticker: CHRS)Upward Pressure
The announcement of a $175 million sales target for LOQTORZI by 2028 signals growth potential, which may boost investor interest in Coherus shares.
This is not investment advice. Market exposure is based on conditional event analysis.
Key Actors
Instruments
Organizations
Source Coverage
FINANCE
3 articles
More coverage on this story
- More on LOQTORZI
- More on Coherus BioSciences
Signals
Single-block coverage
Related Events
▸RxSight projects $120M–$135M revenue for 2026 with commercial pushArchived▸Emergent BioSolutions sets $720M–$760M revenue target for 2026Archived▸Evolv Technology raises 2026 revenue guidance to $178MArchived▸Fastly Q4 2025 presentation slides: Revenue growth accelerates to 23%, achieves profitabilityArchived▸
Primary Sources (3)
FINANCESeeking Alpha - Market NewsCoherus outlines $175M annualized LOQTORZI target by 2028 as commercial expansion acceleratesFINANCESeeking Alpha - Market NewsStereotaxis targets $40M+ annual revenue with manufacturing ramp and product innovation in 2026FINANCESeeking Alpha - Market NewsLifeMD outlines $250M+ annualized revenue run rate target by Q4 2026 amid record GLP-1 demand and expanded partnerships